Clovis Oncology has entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH (3BP), a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need.
Cerevel Therapeutics said that a phase 2 trial assessing orally-administered tavapadon (formerly PF-06649751) in patients with early-stage Parkinson’s disease has met its primary endpoint.
Graybug Vision, a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), announced the initiation of its Phase 2a study with GB-102 in patients with macular edema (ME) secondary to DME or RVO.
Novartis said that the phase 3 trial of its psoriasis drug Cosentyx (secukinumab), called PREVENT, in patients with non-radiographic axial spondyloarthritis (nr-axSpA), has met its primary endpoint at Week 16.
Concert Pharmaceuticals announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in patients with alopecia areata.
POXEL, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the initiation of a Phase 1b double-blind, randomized, placebo-controlled study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics (PK) as well as support dose selection for a pivotal study of PXL065.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3 placebo-controlled clinical trial of patisiran, an intravenously administered RNAi therapeutic, for the treatment of transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented initial top-line clinical data at The Global Summit on Cardiology and Heart Diseases, being held in Dubai, UAE
Novartis’ ofatumumab (OMB157) has achieved the primary endpoints in two phase III trials of relapsing multiple sclerosis (MS).
Celgene Corporation has announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.